Observational studyBMC musculoskeletal disorders2020
Non-surgical treatment with XSHHD for ruptured lumbar disc herniation: a 3-year prospective observational study.
Observational study in BMC musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Computed tomography-guided oxygen-ozone injection for the treatment of lumbar disc herniation complicated with lumbar spinal stenosis.Medical gas research · 2026Article
- Rim enhancement on MRI predicts long-term outcomes in extruded/migrated lumbar disc herniation managed with an inflammation-preserving protocol: a 6-year prospective cohort study.Frontiers in medicine · 2026Article
- Predictive Factors for Resorption in Lumbar Disc Herniation: A Systematic Review.Journal of inflammation research · 2026Review
- Value of contrast-enhanced MRI for predicting resorption of ruptured lumbar disc herniation: a prospective study of 82 cases.Journal of orthopaedic surgery and research · 2025Article
- Mechanisms and management of self-resolving lumbar disc herniation: bridging molecular pathways to non-surgical clinical success.Journal of orthopaedic surgery and research · 2025Review
- Mechanisms and Factors Influencing Resorption of Herniated Part of Lumbar Disc Herniation: Comprehensive Review.Journal of inflammation research · 2025Review
- Effects of oral OsteoKing on pain, lumbar function, and inflammatory markers in patients with lumbar disc herniation.American journal of translational research · 2025Article
- Prevalence, clinical predictors, and mechanisms of resorption in lumbar disc herniation: a systematic review.Orthopedic reviews · 2024Article
- Duhuo Jisheng Decoction suppresses apoptosis and mitochondrial dysfunction in human nucleus pulposus cells by miR-494/SIRT3/mitophagy signal axis.Journal of orthopaedic surgery and research · 2023Article
- Curative Effect of Foraminal Endoscopic Surgery and Efficacy of the Wearable Lumbar Spine Protection Equipment in the Treatment of Lumbar Disc Herniation.Journal of healthcare engineering · 2022Article
- Yaobishu Regulates Inflammatory, Metabolic, Autophagic, and Apoptosis Pathways to Attenuate Lumbar Disc Herniation.Oxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLumbar disc herniation (LDH) is mainly caused by annular fiber disruption with a discrete leakage of nucleus pulposus pressing on a nerve, resulting in back pain and radiating pain. Most patients with LDH can be treated conservatively, but there are many different conservative treatments. Furthermore, most previous studies did not evaluate the long-term efficacy of these treatments and the prognosis. Therefore, an effective and safe therapeutic strategy is lacking for patients with LDH. In this study, we evaluated Xiao Sui Hua He decoction (XSHHD) in the treatment of LDH.
methodsThis was a rigorous prospective observational 3-year follow-up study. We recruited 69 participants with ruptured lumbar disc herniation (RLDH) between February 2014 and February 2016. Patients took XSHHD orally twice a day for 6 months. The primary outcome measurements were visual analogue scale (VAS) pain score, Oswestry disability index (ODI) and straight leg raising test (SLRT). The secondary outcome measurements was nucleus pulposus protrusion volume on magnetic resonance imaging (MRI). Clinical outcomes were measured at baseline (Visit 1), and at 3, 6, 12, and 36 months (Visit 2, 3, 4, and 5, respectively)..
resultsSixty-three patients were followed-up for 3 years after treatment. SLRT and ODI after non-surgical treatment improved significantly compared with baseline (P < .001). There were no statistically significant differences at 6 months vs 36 months for SLRT and ODI. VAS scores (leg, back) after 3 years of treatment were statistically significantly different compared with baseline (P < .001; Z = - 6.93, - 6.637). The baseline protrusion volume was 2018.61 ± 601.16 mm
conclusionsThis study showed that non-surgical treatment with XSHHD was effective, and the study clarified the natural outcomes in LDH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.